Compare Abbott Laboratories (ABT) vs iShares MSCI Australia ETF (EWA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs iShares MSCI Australia ETF — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while iShares MSCI Australia ETF trades at $28.04. The key difference: Abbott Laboratories pays a 2.63% dividend while iShares MSCI Australia ETF pays none, and iShares MSCI Australia ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | EWA | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $30.26 |
52-Week Low | $82.57 | $24.95 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
EWA trades at $28.33, up 0.85% on the day, with technical indicators showing a bearish trend in moving averages and mixed signals from oscillators. The stock faces resistance near $29 and support at $28. Recent news highlights Australian economic headwinds, including missed GDP growth and regulatory changes affecting banks and property markets, which may influence EWA's performance given its exposure to Australian equities.
The outlook for EWA is cautious due to bearish technicals and macroeconomic pressures in Australia. Risks include slower economic growth and sector-specific challenges, but potential opportunities exist if market sentiment improves or if dividend policies attract income-focused investors. Investors should weigh these factors against the current neutral-to-bearish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →
